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Abstract
Human papillomaviruses (HPVs) cause cervical cancer and are associated with the development of non-melanoma skin cancer. A suitable animal
model for papillomavirus-associated skin carcinogenesis is the infection of domestic rabbits with the cottontail rabbit papillomavirus (CRPV). As the
immortalizing activity of CRPV genes in the natural target cells remains unknown, we investigated the properties of CRPV E6 and E7 in rabbit
keratinocytes (RK) and their influence on the cell cycle. Interestingly, CRPVE7 immortalized RK after a cellular crisis but showed no such activity in
human keratinocytes. Co-expressed CRPV E6 prevented cellular crisis. The HPV16 or CRPV E7 protein reduced rabbit pRb levels thereby causing
rabbit p19ARF induction and accumulation of p53 without affecting cellular proliferation. Both CRPVE6 proteins failed to degrade rabbit p53 in vitro
or to bind E6AP; however, p53 was still inducible by mitomycin C. In summary, CRPV E7 immortalizes rabbit keratinocytes in a species-specific
manner and E6 contributes to immortalization without directly affecting p53.
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The infection with high-risk human papillomaviruses (HPV)
is regarded as a necessary risk factor for the development of
cervical cancer (Walboomers et al., 1999). For non-melanoma
skin cancer (NMSC), which is the most common malignancy in
Caucasians worldwide (Miller and Weinstock, 1994; Parker
et al., 1996; Stern, 1999), the identification of high-risk
papillomavirus types is still under debate although epidemiology
and associated risk factors such as age, UV-mediated local and
transplantation-related immune suppression suggest the invol-
vement of an infectious agent (Forslund et al., 2007; Iftner et al.,
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doi:10.1016/j.virol.2007.11.006types, like types 5 and 8, in skin carcinogenesis was found so far
only in patients with the rare genetic disorder epidermodysplasia
verruciformis (EV) that develop HPV-associated warts, which
progress in up to 60% of the individuals into mainly primary
squamous cell carcinomas (Jablonska and Majewski, 1994;
Pfister, 1992). Skin cancer was also recognized as a common
side effect in long-term-immunosuppressed patients as renal
transplant recipients, in whom after an extended period of
immunosuppressive therapy NMSC can be found in up to 70%
(Bouwes Bavinck et al., 1996). HPV-DNA has been detected in
more than 80% of malignant skin tumors of immunosuppressed
patients (Berkhout et al., 1995; Harwood et al., 2000; Shamanin
et al., 1994). Recent studies show that NMSCs of the
immunocompetent general population contain HPV-DNA in
varying percentages (de Villiers, 1998; Harwood et al., 2000;
Iftner et al., 2003). A huge variety of HPV types were detected,
including EV-associated, other cutaneous and genital high- and
low-risk types (Bouwes Bavinck et al., 2001; Lampert et al.,
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cancer (NMSC), especially squamous cell carcinoma even in the
normal population, is therefore very likely.
The underlying mechanisms leading from HPV infection to
invasive skin cancers are, however, not yet fully understood. To
address this question, we use an animal model to study papil-
lomavirus-induced skin tumors in the domestic rabbit infected
with the cottontail rabbit papillomavirus (CRPV) that was
discovered by Shope in 1933 (Rous and Beard, 1935; Shope and
Hurst, 1933). Infection of rabbits with CRPV particles or viral
DNA leads to the development of local tumors within 3 to
6 weeks post-infection. These papillomas progress within 6 to
12 months in more than 80% of the cases into invasive and
metastasizing carcinomas without the need of any other known
cofactors (Jeckel et al., 2002; Syverton, 1952). Therefore, CRPV
provides an excellent in vivo model for studying the malignant
progression and immunological mechanisms of PV-associated
tumors (Brandsma, 2005; Breitburd et al., 1997). CRPVencodes
at least three proteins that confer anchorage independent growth
to immortalized cell lines: CRPV E7, which is encoded in open
reading frame (ORF) E7, and long (LE6) and short E6 (SE6),
encoded in ORF E6 (Meyers et al., 1992). None of the CRPV E6
proteins was previously found to coprecipitate with mouse p53
from embryonal carcinoma cells (Harry and Wettstein, 1996).
The CRPV E7 protein shares some of the properties of HPV16
E7, as both bind pRb, disrupt the complex between pRb and the
transcription factor E2F, transactivate the adenovirus E2
promotor and mediate cellular transformation of rodent
fibroblast lines as measured by growth in soft agar (Defeo-
Jones et al., 1993; Haskell et al., 1993; Schmitt et al., 1994). It
was shown that nearly every ORF of the CRPV genome except
E5 and L2 is required for the development of tumors in the rabbit
model (Brandsma et al., 1991, 1992;Meyers et al., 1992; Nasseri
et al., 1989). However, up to now CRPV genes have not been
demonstrated to be able to immortalize primary cells. Earlier we
have already described the binding affinity for the CRPV E7
protein to the tumor suppressor pRb to be of the relative strength
of 11% to that of HPV16E7 (Schmitt et al., 1994) and found
for CRPV E6/E7 no immortalizing activity in normal human
keratinocytes.
The key function of the HPV16 E7 oncoprotein is the
activation of cell proliferation in the absence of mitogenic
stimuli. This occurs mainly by binding and inactivating pRb
family members, which normally inhibit the E2F transcription
factor family. Activation of E2F results in cell cycle progression
but may also induce p14ARF or its murine homolog p19ARF,
respectively (Bates et al., 1998; Komori et al., 2005). p14/
p19ARF inhibits the ubiquitin ligase activity of mdm2 directed
against p53, thus increasing the half-life of the p53 protein
(Honda and Yasuda, 1999; Zhang et al., 1998).
E7-induced p53 stabilization should induce apoptosis or
growth arrest by the transactivation of proapoptotic genes or p21
respectively. To counteract the antiproliferative and proapoptotic
activities, high-risk type E6 proteins recruit the cellular E3-
ubiquitin ligase E6AP to force the proteasomal degradation of
p53 (Mantovani and Banks, 2001; Scheffner et al., 1990).
However, binding and degradation of p53 by E6 proteins ap-pears to be a unique feature of established genital high-risk types
and has so far not been demonstrated for E6 proteins derived
from low-risk and cutaneous papillomaviruses (Elbel et al.,
1997; Hiller et al., 2006; Steger and Pfister, 1992). Therefore, it
remains an open question how low-risk genital and cutaneous
HPV types escape a p53-mediated growth arrest in spite of the
inability of their E6 proteins to directly target the p53 protein.
As the cell culture system to analyze CRPV's in vitro
properties so far mainly employed already immortalized rodent
cells, as NIH3T3 or SfEP1 (Meyers and Wettstein, 1991), we
aimed to evaluate the immortalizing properties of CRPV in its
natural host cells, normal rabbit keratinocytes. For that reason,
we established and characterized rabbit keratinocyte cell lines
by retroviral transduction with CRPV E6/E7 and as control
HPV16 E6/E7.
Here we show that CRPV E7 on its own was able to
immortalize rabbit keratinocytes after a cellular crisis, whereas
it had no such activity in normal human keratinocytes. Co-
expression of CRPV E6 prevented the cellular crisis of the
transduced rabbit keratinocytes. The E7 protein of CRPVand of
HPV16 reduced the amount of rabbit pRb in the rabbit
keratinocyte lines and caused accumulation of rabbit p19ARF,
which resulted in stabilization of p53. Nevertheless, this had no
negative effect on the cellular proliferation rate. To determine
why p53 is stabilized even in the presence of CRPV E6, we
investigated the interactions between CRPV E6, p53 and E6AP.
The E6 proteins of CRPV and HPV16 failed to bind p53 from
cell lysates of rabbit keratinocytes and to degrade rabbit p53 in
vitro. To clarify the question how CRPV can bypass p53-
mediated growth arrest without being capable of degrading p53,
we analyzed the cellular localization of the stabilized p53 as
well as its expression after DNA damage and proteasomal
inhibition. This revealed a mainly nuclear localization and no
further stabilization of p53 after proteasomal inhibition. Rabbit
p53 was transcriptionally active and still induced p21. In
summary, our data provide evidence that E7 of CRPV is
sufficient to immortalize keratinocytes in a species-specific
mode and that E6 contributes to immortalization but does not
influence rabbit p53 and E6AP directly.
Results
CRPV E7 is able to immortalize rabbit keratinocytes by itself
and in cooperation with CRPV E6
Normal rabbit keratinocytes (NRK) were infected with
recombinant retroviruses. For the combination of CRPV, E6
and E7 simultaneous infection with retroviruses containing
CRPV E6 or CRPV E7, respectively, was used. In the case of
HPV16 E6/E7, we used retroviruses from the pLXSNHPV16E6/
E7 plasmid allowing simultaneous expression of E6 and E7
(Halbert et al., 1991). After infection and drug selection,
resistant cell clones were passaged for more than 6 months. The
results of the long-term growth analysis of the first 2 months are
shown in Fig. 1. The G418-resistant rabbit keratinocyte (RK)
lines obtained after infection with viruses containing CRPV E6,
HPV16 E6 or the parental vectors pZip or pLXSN alone showed
Fig. 1. (A) Long-term growth profile of immortalized rabbit keratinocytes. The number of population doublings (PDs) of the immortalized rabbit keratinocytes (RK)
within 2 months is displayed. PD 0 refers to the point at which drug selection was complete. RK containing CRPV E6/E7, HPV16 E7 or HPV16 E6/E7 demonstrate an
immortalized phenotype. Interestingly, RK-CRPV E7 show immortalization after a certain time span considered as a cellular crisis. Keratinocytes infected with other
retroviral vectors (as pZip, pLXSN, CRPV E6 and HPV16 E6) did not survive drug selection; therefore, they are not included in this graph. (B) Long-term growth
profile of human keratinocytes. In long-term cultivation, the drug-resistant human keratinocytes (HK) cell lines HK-CRPV E6/E7 and HK-HPV16 E6/CRPV E7
showed extended life span. HK with HPV16 E7 and HPV16 E6/E7 were immortalized. The other HK-lines showed similar population doublings compared to the
controls, HK-pZip and HK-pLXSN. (C) Western blot analysis of cytokeratin in different keratinocytes lines. As antibody anti-Cytokeratin Type II (Cymbus
Biotechnology) was used. Normal human or rabbit keratinocytes (NHK or NRK), respectively, served as positive control, rabbit fibroblasts (RF) as negative control.
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are not displayed in the diagram. RK cell lines with CRPV E6/
E7, HPV16 E7 alone or HPV16 E6/E7, however, revealed
immortalized phenotypes as they continued to grow over a
period of more than 6 months. To our surprise, rabbit kera-
tinocytes containing CRPV E7 (RK-CRPV E7) alone were also
immortalized but went at early passages after G418 selection
through a crisis of approximately 21 days marked by very slow
proliferation. After overcoming crisis, the resultant cell line, RK-
CRPV E7, stabilized and became nearly as proliferative as cells
that contained both CRPV E6 and E7 genes (Fig. 1A). The
immortalization assays were repeated at least twice with
keratinocyte populations of different donor rabbits. In order to
confirm that the immortalized populations are derived from
keratinocytes and not of fibroblast origin, we performedWestern
blotting for cytokeratin, using rabbit fibroblasts as a negative
control (Fig 1C).
CRPV E7 is not capable of immortalizing human keratinocytes
but seems to extend life span in combination with CRPV E6 or
HPV16 E6
Normal human keratinocytes were infected with retroviruses
and selected with G418 as described above, yielding thefollowing G418-resistant human keratinocytes (HK) lines:
“HK-pZip”, “HK-pLXSN”, “HK-CRPV E6”, “HK-CRPV E7”,
“HK-HPV16 E6”, “HK-HPV16 E7”, “HK-HPV16 E6/E7”,
“HK-CRPV E6/E7” and “HK-CRPV E7/HPV16 E6”. In long-
term cultivation, the resistant cell lines HK-CRPV E6/E7 and
HK-HPV16 E6/CRPV E7 demonstrated a slightly extended life
span. HK containing HPV16 E7 and HPV16 E6/E7 were
immortalized. The other HK lines showed similar passage
number compared to human keratinocytes containing pZip or
pLXSN before they stopped growing. In contrast to its
immortalizing properties in rabbit keratinocytes, CRPV E7 by
itself was not able to immortalize human keratinocytes but
seemed to confer even retarded growth (Fig. 1B).
The presence and expression of the viral genes in the rabbit
cell lines is detectable by PCR and RT-PCR
For verification of the presence of the retrovirally transduced
CRPVor HPV16 E6 and E7 genes in the immortalized RK lines,
PCR was performed. AVS cells, containing the complete CRPV
genome and SiHa cells, containing HPV16, respectively, were
used as positive controls, as shown in Fig. 2A. This analysis
clearly shows the presence of the correct DNA in the respective
cell lines and excludes cross contamination. To confirm the
Fig. 2. (A) PCR analysis of CRPV and HPV16 E6 and E7 genes in the
immortalized rabbit lines. Total cellular DNA was extracted from pelleted
culture cells and PCR was performed with specific primers for CRPV and
HPV16 E6 and E7. Aliquots were separated in an agarose gel and visualized by
ethidium bromide staining. AVS cells, containing the complete CRPV-genome,
and SiHa cells, containing HPV16, respectively, were used as positive controls.
Negative control samples contained no template DNA. (B) Reverse transcription
PCR analysis for E6 and E7 expression in the stable rabbit keratinocyte lines.
Total RNA was isolated from the immortalized rabbit keratinocytes lines and
reverse transcribed with specific primers for E6 and E7 of CRPV and HPV16,
following amplification by PCR. The negative control reactions contained PCR
mixture without template DNA. HK-HPV16 E6/E7 and HK-HPV16 E7 or AVS
cells were used as positive control for HPV16 or CRPV, respectively. Aliquots were
separated in an agarose gel and visualized by ethidium bromide staining. Left:
Arrows indicate specific PCR products, stars indicate unspecific products or
primers. In the case of HPV16 E6 primers, spliced and unspliced E6 are detectable.
Fig. 3. Quantitative analysis of pRb levels in immortalized rabbit keratinocytes.
Western blots of pRb (M-135, Santa Cruz) were performed and pRb and
α-tubulin signals were quantified as described in Materials and methods. Normal
human keratinocytes and HPV16 E7 expressing human keratinocytes served as
positive control. The human pRb and rabbit pRb signals were corrected for the
respectiveα-tubulin signals and are presented relative to the signals obtained with
normal human keratinocytes (NHK) or normal rabbit keratinocytes (NRK),
respectively, which were set to 1. (A) Representative Western blot including
α-tubulin as loading control. Molecular weight (mol wt) in kilodalton is presented
on the left. (B) Average relative amount of pRb. The columns represent the
average of at least three independent Western blots; the bars show the standard
deviation.
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presented in Fig. 2B. Transcription of the viral genes was
detectable in all cell lines. With primers for HPV16 E6, the
unspliced E6/E7 mRNA and the spliced E6 mRNA were
detectable. Quantitative real time PCR analysis (see Supple-
mentary data) revealed comparable levels of E7 transcripts in
rabbit or human keratinocytes expressing HPV16E6/E7 or
HPV16 E7, which was not provided by the data from the solely
qualitative analysis in Fig. 2B. The quantitative analysis also
showed no differences in the levels of spliced and unspliced E6
transcripts in rabbit versus human cells.The level of rabbit pRb is diminished in the rabbit cell lines
The key function of HPV16 E7 is to degrade pRb to activate
the cell cycle, which also leads to the accumulation of p14ARF
via E2F. Because we have already shown earlier that CRPV E7
is able to bind pRb (Schmitt et al., 1994), we analyzed the
amount of rabbit pRb in the rabbit keratinocyte lines containing
HPV16 or CRPV E7 proteins. Quantitative Western blot anal-
ysis revealed that rabbit pRb levels are strongly reduced in all
RK cell lines compared to levels in normal rabbit keratinocytes
as shown in Fig. 3. Untreated normal human keratinocytes
(NHK) and human keratinocyte lines with HPV16 E7 served as
control.
Detection of increased amounts of the cell cycle proteins
p19ARF, mdm2, p53 and p21 in the rabbit keratinocyte lines
To investigate alterations in the pRb-p53 pathway in the
immortalized rabbit cell lines, we analyzed protein levels of
rabbit homologs of p19ARF, mdm2, p53 and p21. Western blot
analysis demonstrated in all immortalized cell lines increased
317T. Ganzenmueller et al. / Virology 372 (2008) 313–324levels of rabbit p19ARF, mdm2, p53 and p21 as compared to
normal rabbit keratinocytes as control (Fig. 4).
None of the CRPV E6 proteins is able to degrade human or
rabbit p53 in vitro
As previously shown, neither long nor short E6 of CRPV
were capable of binding p53 from F9 mouse embryonal
carcinoma cells (Harry and Wettstein, 1996). Thus, we wanted
to verify these data for rabbit p53 using in vitro degradation
assays. As shown in Fig. 5A, HPV16, HPV18 E6 or CRPV E6
is not able to degrade rabbit p53 in vitro. Human p53 is
degraded efficiently by E6 of HPV16 and HPV18, but not by
CRPV E6.
CRPV E6 is in contrast to high-risk E6 unable to bind rabbit
E6AP
The main feature of high-risk HPV E6 proteins is their ability
to recruit the E3-ubiquitin ligase E6AP and alter its substrate
specificity towards p53. Because our data showed that CRPV,
HPV16 and HPV18 E6 failed to degrade rabbit p53, we
analyzed in MBP pull-down assays whether this is due to theFig. 4. Protein levels of the p19ARF/p53 pathway proteins in rabbit keratinocytes.
Lysates of the immortalized rabbit keratinocytes (RK) were analyzed by SDS–
PAGE and immunoblotting for p19ARF (14P03/ DCS-241, Neomarkers), mdm2
(SMP14, Santa Cruz), p53 (DO-1, Santa Cruz) and p21 (SX-118, Pharmingen)
proteins. Measurements were repeated several times; here representative
Western blot stainings are shown for each protein including α-tubulin (Ab-1,
Calbiochem) as a loading control. On the left, the molecular weight (mol wt) in
kilodalton is displayed.inability to interact with rabbit E6AP. MBP fusion proteins of
CRPV LE6, SE6, HPV16 or HPV18 E6 were incubated with
cell extracts from RK-CRPV E7 and tested for interaction with
rabbit E6AP and rabbit p53. Extracts from HEK293 cells
incubated with HPV16 and HPV18 E6 fusion proteins served as
positive control. As shown in Fig. 5B, HPV16 and HPV18 E6
were able to bind both rabbit and human E6AP, whereas CRPV
LE6 and SE6 revealed no affinity to rabbit E6AP. Confirming
our data from the in vitro degradation assay, rabbit p53 showed
no interaction with HPV16 or HPV18 E6, whereas human p53
did. None of the CRPV E6 proteins were able to retain rabbit
p53 on the column.
Inhibition of the proteasome does not influence the rabbit p53
levels in rabbit keratinocytes
Inhibition of proteasomal activity with MG-132 in HeLa
cells resulted in an accumulation of p53 compared to control
cells. In contrast, no significant change of rabbit p53 amount
was detected in rabbit keratinocytes containing CRPV E7 or
CRPV E6/E7, as shown in Fig. 6.
Induction of rabbit p53 by treatment with mitomycin C
To analyze if rabbit p53 is still inducible and transcription-
ally active by DNA damage, we treated the rabbit keratinocyte
lines with mitomycin C (MMC), which causes damage of
DNA by alkylation and cross-linking and thereby p53 accumu-
lation (Abbas et al., 2002; Hess et al., 1994). Normal rabbit
keratinocytes (NRK) and normal human keratinocytes (NHK)
served as controls. In Fig. 7, we demonstrate that MMC
treatment caused stabilization of rabbit or human p53 in all
treated cell lines, which was accompanied by increased cell
death of the treated versus non-treated cells. Subsequent rabbit
or human p21 accumulation was detected in the MMC-treated
immortalized rabbit keratinocyte cell lines and NHK. P21
showed no detectable levels in normal rabbit keratinocytes.
Rabbit p53 is localized mainly in the nucleus
P53 signaling can be influenced by altering the subcellular
localization, for example, by nuclear exclusion. To investigate
the phenomenon of increased rabbit p53 expression in un-
affectedly proliferating rabbit keratinocyte lines, we analyzed
rabbit p53 localization by immunofluorescence staining. As
shown in Fig. 8, rabbit p53 localized strictly to the nuclei in all
cell lines, except for RK-CRPV E6/E7 that revealed in addition
to the nuclear staining a distinct rabbit p53 signal in the
cytoplasm.
Discussion
To investigate the immortalizing properties of the cottontail
rabbit papillomavirus (CRPV), we established human and for
the first time rabbit keratinocyte lines stably expressing CRPV
or HPV16 E6 and E7 together or separately after retroviral gene
transfer.
Fig. 5. In vitro biological properties of the E6 proteins of CRPV, HPV16 and HPV18. (A) E6-mediated degradation of human and rabbit p53 in vitro. In vitro translated
p53 was incubated with in vitro translated E6 protein of CRPV, HPV16 and HPV18 or water-primed lysate (H2O) for 2 h. On top of the figure, an autoradiogram of a
representative degradation assay is displayed. At the bottom, the average relative amounts of p53 remaining after 2 h of incubation quantified by phosphoimaging are
shown. Data are relative to the water-primed control, which was set to 100%. The columns represent the average of at least three independent experiments, the bars the
standard deviation. (B) In vitro ability of E6 proteins of CRPV, HPV16 and HPV18 E6 to interact with rabbit p53 and E6AP in MBP pull-down assays. RK-CRPV E7
and HEK293 cells were lysed and incubated with immobilized MBP fusion proteins of CRPV short and long E6 as well as HPV16 or HPV18 E6. Beads were washed
and MBP-E6 and interacting proteins were eluted via maltose. Proteins were analyzed by SDS–PAGE and Western blotting using anti-p53 (DO-1, Santa Cruz) and
anti-E6AP (H-182, Santa Cruz) antibodies. On the left, the molecular weight (in kDa) in kilodalton is displayed.
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itself after overcoming cellular crisis or by CRPV E6 and E7
together without crisis. Interestingly, CRPV E7 by itself was not
able to alter life span of human keratinocytes. Thus, CRPV E7
showed species-specific differences with regard to its immorta-
lizing abilities in human and rabbit keratinocytes. However,
expression of CRPV E6/E7 or a combination of CRPV E7 and
HPV16 E6 in human keratinocytes caused only a slightly
prolonged life span, in contrast to the HPV16 E7- or HPV16 E6/
E7-mediated immortalization of human keratinocytes that has
been described before (Halbert et al., 1991; Hawley-Nelson
et al., 1989; Munger et al., 1989). Interestingly, HPV16 E7 and
HPV16 E6/E7 were able to overcome the species barrier and to
immortalize rabbit keratinocytes, underlining their properties as
potent oncogenes.Because CRPV E7 is sufficient to immortalize normal rabbit
keratinocytes by itself, the situation is comparable to the HPV16
E7-mediated immortalization of human keratinocytes (Hawley-
Nelson et al., 1989; Munger et al., 1989). Further CRPV E6
expressed together with E7 omitted the cellular crisis observed
with E7 only and therefore cooperated in the immortalization
process like HPV16 E6 as reported previously (Halbert et al.,
1991). However, it must be taken into account that HPV16 E6 is
able to degrade p53, whereas CRPV E6 is neither capable of
degrading human or rabbit p53 nor capable of interacting with
E6AP, as we have shown here. CRPV E6 alone did not exhibit
immortalizing abilities in rabbit or human keratinocytes but
revealed transforming activities in fibroblast lines as shown
earlier (Meyers et al., 1992; Schmitt et al., 1994). Thus, the
mechanism how the E6 proteins of CRPV do accelerate the
Fig. 6. Analysis of p53 after proteasomal inhibition with MG-132. RK-CRPV
E6/E7, RK-CRPV E7 or HeLa cells were incubated with 0.1% DMSO or 10 μM
of the proteasome inhibitor MG-132 solved in 0.1% DMSO for 6 h for RK and
4 h for HeLa cells. Untreated cells are marked by (−). Cells were lysed and rabbit
or human p53 (DO-1, Santa Cruz) and α-tubulin as a loading control were
detected by Western blotting. One representative Western blot analysis is shown
here. The molecular weight (mol wt) in kilodalton is displayed on the left.
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In contrast to HPV E6 proteins, there is very little known about
CRPV E6's cellular interaction partners. CRPV E6 could
possibly affect telomerase activity, as reported for HPV16 E6
(Mantovani and Banks, 2001), a property that is independent of
the ability to degrade p53 and is not sufficient for immortaliza-
tion of cells (Klingelhutz et al., 1996). However, CRPV E6's
deficiency to bind E6AP makes this highly unlikely (Gewin
et al., 2004). Unfortunately, with the currently available rabbit
genomic data, we failed to detect a rabbit mRNA homologous
to any known TERT cDNA and could not test for rabbit
telomerase induction (data not shown). The influence of CRPV
E6 on Bak, a proapoptotic protein, which is targeted by genital
and cutaneous HPVs (Jackson et al., 2000; Thomas and Banks,
1999), could not be analyzed because the commercially
available antibodies were not functional for detection of the
rabbit homolog. Recently, an association of CRPV E6 proteins
with the hDLg/SAP97 tumor suppressor protein was demon-
strated. High-risk HPV E6 proteins bind and target hDlg for
degradation, whereas CRPV E6 did not lead to degradation of
hDlg (Du et al., 2005). This finding can be confirmed by our
data showing the inability of CRPV E6 to bind the ubiquitin
ligase E6AP, an interaction that seems to be necessary for degra-
dation of hDlg (Kuballa et al., 2007). Further investigations
are necessary to clarify the mechanism of CRPV E6's ability
to cooperate with E7 in immortalization of rabbit keratinocytes.Fig. 7. Levels of rabbit p53 and p21 protein after mitomycin C treatment of NRK,
mitomycin C (MMC) in K-SFM for 14 h (designated as “+MMC”) and lysed afterwar
PAGE and immunoblotting for p53 (DO-1, Santa Cruz) and p21 (SX-118, Pharmingen
blot is shown including the loading control α-tubulin. Molecular weight (mol wt) inCRPV E7 seems to be the major immortalizing factor in
rabbit keratinocytes and thus comparable to high-risk HPV E7
proteins. A main feature of HPV16 E7 in carcinogenesis is its
ability to associate with human pRb and promote its degradation
via the proteasome pathway (Munger et al., 2001). The 14-kDa
CRPV E7 protein shares some biological properties with
HPV16 E7: both bind human pRb at the same C-terminal
domain and disrupt the complex between pRb and the transcrip-
tion factor E2F. CRPV E7 shows 11–12% relative binding to
human pRb compared to HPV16 E7 (Defeo-Jones et al., 1993;
Haskell et al., 1993; Schmitt et al., 1994). Here we demonstrate
that both CRPV and HPV16 E7 were able to reduce rabbit
pRb levels in rabbit keratinocytes. Treatment of the CRPV E7
containing rabbit keratinocytes with the proteasome inhibitor
MG-132 led to enhanced amounts of pRb, referring to a
mechanism for pRb reduction linked to the proteasomal
degradation machinery (data not shown). Taken together, this
supports the assumption that CRPV E7 is using an inactivation
mechanism of rabbit pRb comparable to the mechanism of
HPV16 E7 and that this ability of CRPV E7 could explain its
competence to immortalize rabbit cells. However, there might
be additional events necessary taking into account the cellular
crisis before rabbit keratinocytes become immortalized.
Rabbit keratinocytes immortalized by the CRPV or HPV16
E7 and E6/E7 genes demonstrate a steep rise of rabbit p19ARF,
probably due to the degradation of rabbit pRb by E7 and
subsequent release of E2F transcription factors as shown for the
murine/human system before (Bates et al., 1998; Komori et al.,
2005). According to the model, this will cause inhibition of
rabbit mdm2 and accumulation of rabbit p53 (Honda and
Yasuda, 1999; Zhang et al., 1998), an instance which could be
demonstrated here in all immortalized rabbit keratinocytes.
These findings suggest a pRb pathway operating in rabbit cells
similarly to the human system and stress the resemblance of the
E7 of CRPVand HPV16. However, in the case of HPV16 E7, it
has been reported that p53 stabilization is independent of
p19ARF (Seavey et al., 1999), as shown in mouse embryo
fibroblasts lacking p19ARF. We cannot rule out this point
completely for the rabbit keratinocytes in our experiments.
In order to further enlighten the p53 stabilization in the rabbit
keratinocytes, we analyzed the interactions between p53, E6APNHK and immortalized rabbit keratinocytes. Cells were treated with 7 μg/ml
ds. Negative controls received K-SFM only. Cell lysates were analyzed by SDS–
). The measurement was repeated at least twice; here one representative Western
kilodalton is displayed on the left.
Fig. 8. Immunofluorescence analysis of p53 in rabbit keratinocyte lines. The localization of p53 in the different rabbit cell lines was evaluated by staining of nuclei by
4′,6-diamidino-2-phenylindole (DAPI) and immunostaining of rabbit p53 (DO-1, Santa Cruz) and a Cy3-labeled secondary antibody. The third column shows the
merge of the first two columns.
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none of the CRPV E6 proteins were able to degrade rabbit or
human p53. Interestingly, HPV18 E6 was neither able to bind
nor to degrade rabbit p53 in vitro. The inability of HPV18 E6 to
interact with rabbit p53 might be due to species-specific
structural differences as it is capable of efficiently binding and
degrading human p53. An alignment of human and rabbit p53
showed 85% conservation on the amino acid level (data not
shown). In addition, the CRPV E6 proteins were unable to
interact with rabbit E6AP, whereas HPV18 E6 was able to bind
rabbit E6AP. These results indicate that the complex formation
of E6, E6AP and p53, a common feature for high-risk HPV E6
(Scheffner et al., 1993), does not occur in rabbit keratinocytes.
Obviously, the transcriptional modulation functions that have
been described for the human E6–E6AP complex (Kelley et al.,
2005) are dispensable for tumor formation in the rabbit.
Hence, the question arises, how a p53-mediated growth
arrest is abrogated. This situation is comparable to the setting in
HPV16 E7 expressing human cells, which display stabilized
p53 resulting from an extension of its half-life, but uncompro-
mised growth abilities (Demers et al., 1994; Eichten et al., 2002;
Jones et al., 1997; Jones and Munger, 1997). In this case, it
has been demonstrated that the stabilized p53 in HPV16 E7expressing cells is transcriptionally inert (Eichten et al., 2002)
and that p21 expression is increased by protein stabilization
rather than through p53-mediated transcriptional induction (Jian
et al., 1998; Jones et al., 1999).
As HPV16 E7 can interact with the S4 subunit of the 26S
proteasome (Berezutskaya and Bagchi, 1997), we studied
whether p53 might be stabilized in the immortalized rabbit
keratinocytes by interference with the proteasomal degradation
system. We could demonstrate that the p53 level in both CRPV
E7 and CRPV E6/E7 containing RK cells was not influenced by
inhibition of the proteasome with MG-132. This indicates that
probably rabbit mdm2 is blocked by p19ARF and mainly
responsible for rabbit p53 degradation, as there is no further
increase of rabbit p53 after proteasomal inhibition.
In contrast, we could demonstrate by treatment of the rabbit
cell lines with mitomycin C (MMC) that the stabilized rabbit p53
is inducible by DNA damage signaling. Interestingly, rabbit p21
levels also increased in response to MMC treatment implying an
intact p53 transactivation.
Another possibility of interfering with p53 functions is the
mutations of p53 occurring within the process of immortali-
zation. It has been reported that p53 is often mutated in skin
tumors (Ananthaswamy and Pierceall, 1992). However, because
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this suggests a wild-type p53 transactivation function. Further-
more, exclusively wild-type rabbit p53 sequence was found in
CRPV containing carcinomas and papillomas (S. Tkaczik,
unpublished data).
In addition we tested whether rabbit p53 is functionally
inactivated by nuclear exclusion. This has been reported for
different carcinomas (Bosari et al., 1995; Moll et al., 1992;
Schlamp et al., 1997) or for viral oncoproteins, which are able to
mislocalize p53 to the cytoplasm (Elmore et al., 1997; van den
Heuvel et al., 1993). Here we show by immunofluorescence
analysis that in the immortalized rabbit keratinocytes no
dramatic shift in the subcellular localization was observed for
rabbit p53, but CRPV E6 seems to affect a minor amount of total
rabbit p53 with respect to its nuclear localization. This finding
might give hints to additional CRPV E6 functions. However, the
exact mechanism, how CRPV E7 does abolish p53-mediated
growth arrest or apoptosis, remains unclear.
Taken together, CRPV E7 was able to immortalize normal
rabbit keratinocytes by itself after going through a crisis. The
immortalization by CRPV E7 was enhanced by co-expression of
CRPV E6 preventing cellular crisis. The immortalized rabbit
cells showed high proliferation but contained elevated levels of
rabbit p53, probably due to p19ARF-mediated mdm2 inhibition
caused by degradation of rabbit pRb via CRPV E7. Rabbit p53
was still inducible by DNA damage and displayed wild-type
functions. Our findings validate the rabbit animal model by
showing immortalizing abilities of CRPV E7 in rabbit
keratinocytes thereby stressing the role of papillomaviruses in
cutaneous carcinogenesis. The established cell culture system
complements the animal system giving the possibility to
evaluate in vitro properties of CRPV and thus provides a
valuable tool for the further investigation of mechanisms leading
to skin cancer.
Materials and methods
Cell culture
Primary human foreskin keratinocytes designated as NHK
(normal human keratinocytes) were isolated from neonatal
foreskins as described (Ruesch et al., 1998) and cultivated in
complete keratinocyte serum-free medium (K-SFM) (Invitro-
gen, Karlsruhe, Germany) supplemented with gentamicin
(0.5 mg/mL). Primary rabbit keratinocytes were isolated from
New Zealand White rabbit skin as followed: Approximately
2×3 cm sized rabbit skin pieces were washed several times in
PBS, incubated with 10 ml dispase (2.4 U/l) (Roche) for 4 h at
37 °C. After disconnection from the subcutis, the epidermis was
incubated for 10 min with trypsin (0.25% trypsin, 1 mM
EDTA) (Invitrogen) followed by mechanical disruption,
inactivation of trypsin and purification by using a cell strainer
(Falcon, Becton Dickinson, Heidelberg, Germany). After
centrifugation, cells were plated on Primaria culture dishes
(Falcon) and designated as NRK (normal rabbit keratinocytes).
Primary cultures, resulting cell lines and AVS cells (rabbit
keratinocytes containing the complete CRPV genome; Huber etal., 2004), were maintained in complete K-SFM without
antibiotics. Cells were used for retroviral infection within a
few days after isolation. SiHa, HeLa, HEK293 and Phoenix cells
were maintained in D-MEM (Invitrogen) with 10% of bovine
calf serum. All cells were cultivated at 37 °C and 5% CO2 in
humidified atmosphere.
Generation of amphotropic retroviruses
High-titered amphotropic recombinant retroviruses were
generated by transient transfection of retroviral vectors into
Phoenix cells (ATCC # SD 3443) using the calcium phosphate
precipitation method. The following plasmids were used:
pZipNeo SV(X)-1 (Cepko et al., 1984), pZipNeoCRPVE6,
pZipNeoCRPVE7 (Meyers et al., 1992), pLXSN (Clontech,
Heidelberg, Germany), pLXSNHPV16E6, pLXSNHPV16E7
and pLXSNHPV16E6/E7 (Halbert et al., 1991).
Retroviral infection of normal keratinocytes
Forty-eight hours after transfection of Phoenix cells, the cell
culture supernatants were filtered through 0.45-μm sterile filters,
and 2 ml aliquots was mixed with 4 ml of K-SFM and 4 μg/ml
polybrene (Sigma). The mixture was incubated for 8 h with
NHK or NRK cells grown on 100-mm-diameter dishes to 70%
confluency. Then G418 selection (50 μg/ml) was applied for
10 days. Coinfection was carried out by using two different
supernatants simultaneously. Stable G418-resistant cell lines
were maintained in supplemented K-SFM and long-term growth
was monitored. Rabbit keratinocytes (RK) lines were designated
as RK-CRPV E7 (pZipCRPVE7), RK-CRPV E6/E7 (coinfec-
tion with pZipCRPVE6 and pZipCRPVE7), RK-HPV16 E7
(pLXSNHPV16E7) and RK-HPV16 E6/E7 (pLXSNHPV16E6/
E7), human keratinocytes (HK) lines as “HK-pZip” (pZipNeo),
“HK-pLXSN” (pLXSN), “HK-CRPV E6” (pZipCRPVE6),
“HK-CRPV E7” (pZipCRPVE7), “HK-HPV16 E6”
(pLXSNHPV16E6), “HK-HPV16 E7” (pLXSNHPV16E7),
“HK-HPV16 E6/E7” (pLXSNHPV16E6/E7), “HK-CRPV E6/
E7” (coinfection with pZipCRPVE6 and pZipCRPVE7) and
“HK-CRPV E7/HPV16 E6” (coinfection with pZipCRPVE7
and pLXSNHPV16E6).
Long-term growth analysis of stable cell lines
To determine the number of population doublings (PDs) of
the stable human or rabbit keratinocytes over a certain time
period, we grew the cells on 100-mm-diameter dishes and
trypsinized when they reached approximately 80% confluence.
PDs were calculated taking into consideration the number of
passages and split ratio.
Drug treatments of culture cells
Rabbit keratinocyte lines were treated with 7 μg/ml mito-
mycin C (MMC) (medac, Wedel, Germany) in K-SFM at a
confluence of about 70% for 14 h. Control cells received fresh
culture medium without MMC.
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mately 1×107 HeLa or 3×106 RK-CRPV E7 and RK-CRPV
E6/E7 cells, respectively, were incubated with 0.1% DMSO or
0.1% DMSO and 10 μM proteasome inhibitor MG-132
(Calbiochem, Merck-Biosciences, Darmstadt, Germany). Incu-
bation time was 6 h for RK and 4 h for HeLa cells, followed by
trypsinization, lysis in NP40 lysis buffer (130 mMNaCl, 50 mM
Tris pH 8.0, 1 mM EDTA, 1% NP-40, 1 mM DTT) and analysis
by quantitative Western blotting.
PCR
Pelleted cultured cells (2×106) were incubated with protein-
ase K followed by extraction of total DNA using the Biorobot
EZ-1 and the EZ-1 DNATissue kit (Qiagen, Hilden, Germany)
according to manufacturer's instructions. PCR was performed
with 200 ng of cellular DNA and 40 pmol of oligonucleotides
using AmpliTaq Gold DNA Polymerase (Applied Biosystems,
Darmstadt, Germany) under following PCR conditions:
5 min 95 °C; 40 cycles with 1 min 95 °C, 30 s 55 °C, 60 s
72 °C; 10 min 72 °C. The primer sequences were as follows:
CRPV E6: 155 forward TGGAGAACTGCCTGCCACG, 693
reverse TTCCTCCAGATCCACCGGAG; CRPV E7: 1081
forward GGCAGAACTCCTAAGCTTAGTGAGC, 1359
reverse TCAGTTACAACACTCCGGGCA; HPV16 E6: 140
forward CCACAGTTATGCACAGAGCT, 557 reverse
ACAGCTGGGTTTCTCTACGTGTTC; HPV16 E7: 563 for-
ward TGCATGGAGATACACCTACATTGC, 853 reverse
GTTTCTGAGAACAGATGGGGCA.
Reverse transcription PCR
Total RNAwas isolated from cultured cells with the RNeasy-
Kit (Qiagen) according to the manufacturer's instructions includ-
ing on-column DNase-treatment. Reverse transcription was
performed using the Superscript II Reverse Transcriptase (Invitro-
gen), random hexamer oligonucleotides and 2 μg of total RNA as
recommended by the manufacturer. cDNA was amplified using
the GoTaq-DNA-Polymerase (Promega, Mannheim, Germany)
according to manufacturer's instructions and the following primer
pairs: CRPVE6 446 forward GCGTTGTACAGTTTGCGGA and
800 reverse ACCCCCCTCCTCGTCTTCTTCCC; HPV16 E6
101 forward GCAATGTTTCAGGACCCACAG and 557 reverse
ACAGCTGGGTTTCTCTACGTGTTC; further CRPV E7 1081
forward and 1359 reverse and HPV16 E7 563 forward and 853
reverse as described above.
Western blot analysis
Total cell extracts were prepared with M-PER mammalian
protein extraction reagent (PerbioScience, Bonn, Germany)
according to the manufacturer's instructions. Protein concentra-
tions of the extracts were determined by the Micro BCA Protein
Assay Reagent Kit (PerbioScience). Probes with equal protein
concentrations were run on SDS–polyacrylamide gels, trans-
ferred to nitrocellulose, blocked and incubated afterwards with
the primary antibody overnight. The following antibodies wereused: mdm2 (SMP14, mouse monoclonal, Santa Cruz Biotech-
nology, Heidelberg Germany), P14ARF/p16β Ab-3 (Clone
14P03/ DCS-241, mouse monoclonal, Neomarkers), p21 (SX-
118, mouse monoclonal, Pharmingen BD-Biosciences, Heidel-
berg, Germany), p53 (DO-1, mousemonoclonal, Santa Cruz),α-
Tubulin (Ab-1, mouse monoclonal, Calbiochem), pRb (M-135,
rabbit polyclonal, Santa Cruz), Cytokeratin Type II (mouse
monoclonal, Cymbus Biotechnology) and E6AP (H-182, rabbit
polyclonal, Santa Cruz). The respective secondary antibodies
were conjugated to horseradish peroxidase. Blots were devel-
oped with SuperSignal West Femto (PerbioScience) as a sub-
strate and visualized by the Fluor-SMaxMultiImager (Bio-Rad,
München, Germany). Band intensities were quantified using the
Quantity One Quantitation software package (version 4) (Bio-
Rad) and signals were normalized against the respective levels of
α-tubulin to correct for unequal loading of the gels.
In vitro degradation assays
Plasmids Rc/CMV-p53, pcDNA3.1D-16 E6 and pcDNA3.
1D-18 E6 were previously described (Hiller et al., 2006). The
CRPV E6 gene was amplified by PCR using the cloned CRPV
genome as a template and cloned into pSG5 and verified by
sequencing. Rc/CMV-p53 or pSG5/pcDNA3.1-E6 plasmidswere
transcribed and translated separately in vitro using the TNT
coupled rabbit reticulocyte lysate system (Promega) in the
presence of [35S]-methionine (N1000 Ci/mmol) or [35S]-cysteine
(N1000 Ci/mmol) (Amersham, Munich, Germany), respectively,
according to the manufacturer's instructions. An aliquot of each
translation reaction was separated by SDS–PAGE and exposed to
image screens, and the amount of labeled proteins was then
quantified by using a BAS-1800 PhosphoImager (Fujifilm) and
the AIDA software version 2.0 (Raytest, Straubenhardt, Ger-
many). After correcting for the different amounts of cysteines or
methionines, respectively, normalized amounts of E6 proteins
were mixed with p53 at a ratio of 1:11. Volumes were adjusted
using water-primed lysate. Reaction mixtures were incubated at
30 °C for 2 h. The residual proteins were resolved by SDS–PAGE
and visualized as described above.
Maltose binding protein pull-down assays
HPV16 E6, HPV18 E6 and CRPV LE6 and SE6 were cloned
into the pMal-c2x plasmid (NEB, Frankfurt, Germany) yielding
pMal-c2X-HPV16E6, pMal-c2X-HPV18E6, pMAL-c2X-
CRPVLE6 and pMAL-c2X-CRPVSE6. Transformed Escheri-
chia coli BL21 CDE3 Rosetta2 bacteria were grown to an
OD600 of 0.6, cells were shifted to 20°C and then 0.5 mM IPTG
was added for 1 h. Cells were harvested by centrifugation; pellets
were resuspended in 1 ml of TMN-buffer (50 mM Tris pH 8.0,
12.5mMMgCl2, 0.1%NP-40, 0.1%DTT) and then disrupted by
ultrasonication (Bandelin Sonoplast UW2200) on ice. Cleared
supernatants were incubated with 50 μl of amylose agarose
beads (NEB) for 1 h at 4 °C and then extensively washed with
TMN buffer. RK-CRPV E7 and HEK293 cells were harvested
by trypsinization and lysed in NP40 lysis buffer (130 mMNaCl,
50 mM Tris pH 8.0, 1 mM EDTA, 1% NP-40, 1 mMDTT). Cell
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immobilized maltose binding protein (MBP) fusion proteins
for 2 h at 4 °C. Subsequently, the resin was washed several times
with TMN buffer and the retained proteins were eluted with
TMN buffer containing 20 mM maltose and analyzed by
Western blotting.
Immunofluorescence microscopy
For indirect immunofluorescence microscopy analysis, cells
were grown on MatTek glass bottom culture dishes (MatTek
Corp., Ashland, MA), fixed in 4% paraformaldehyde for 10 min
and permeabilized with 0.2% Triton-X. Staining was performed
with p53 antibody (DO-1, Santa Cruz) diluted 1:100 in PBS/3%
bovine serum albumin or appropriate controls for 1 h at room
temperature. Cells were subsequently washed four times with
PBS and incubated with Cy3-conjugated anti-mouse IgG
antibodies diluted 1:300 in PBS/3% bovine serum albumin.
Unbound antibody was removed by extensive washing with
PBS; 4′,6-diamidino-2-phenylindole (DAPI) in PBS was briefly
added to stain for DNA and then unbound DAPI was removed
by washing with PBS. Fluorescence signals were visualized
with a Zeiss Axiovert 200 M microscope featuring the
ApoTome technique and the respective fluorescence filter sets
for DAPI and Cy3. Pictures were taken with an AxioCamMRm
camera and processed with AxioVision software version 4.3
(Carl Zeiss AG, Oberkochen, Germany).
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